A study on the efficacy and Safety Evaluation of a novel PD-1/CTLA-4 bispecific antibody
Tumors constitute a significant health concern for humans, and PD-1 and CTLA-4 monoclonal antibodies have been proven effective in cancer treatment. Some researchers have identified that the combination of PD-1 and CTLA-4 dual blockade demonstrates superior therapeutic efficacy. However, the develop...
Saved in:
Main Authors: | Qi Song, Meiling Jiang, Xinrong Pan, Guanyue Zhou, Xiaomeng Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-11-01
|
Series: | Immunobiology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0171298524000627 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The efficacy and safety of a novel PD‐1/CTLA‐4 bispecific antibody cadonilimab (AK104) in advanced non‐small cell lung cancer: A multicenter retrospective observational study
by: Hongxin Li, et al.
Published: (2024-11-01) -
Case report: Complete response in TMB-H advanced uterine clear cell carcinoma: a case analysis of paclitaxel albumin-bound combined with PD-1/CTLA-4 bispecific antibody
by: Yue Chen, et al.
Published: (2024-12-01) -
Polymeric Multivalent Fc Binding Peptides‐Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA‐4
by: Zongyu Liu, et al.
Published: (2025-01-01) -
Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma
by: Giulio Cassanello, et al.
Published: (2024-12-01) -
Blockade of CCR5+ T Cell Accumulation in the Tumor Microenvironment Optimizes Anti‐TGF‐β/PD‐L1 Bispecific Antibody
by: Ming Yi, et al.
Published: (2024-11-01)